- NCIt
- C5115
Loading cancer entity…
Loading cancer entity…
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01414738 |
| Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases |
| completed |
| Phase 2 |
| 50 |
| University of Texas Southwestern Medical CenterOTHER |
| 1 |
| Jan 26, 2021 |
| clinicaltrials |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2019 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00939484 | Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 3, 2025source: clinicaltrials